DNA Damage Response Gene-Based Subtypes Associated With Clinical Outcomes in Early-Stage Lung Adenocarcinoma

• DOI: 10.3389/fmolb.2022.901829
• Publication Date: 2022-06-22T06:06:03Z
• Authors: Yang Zhao; Bei Qing; Chunwei Xu; Jing Zhao; Yuchen Liao; Peng Cui; Guoqiang Wang; Shangli Cai; Yong Song; Liming Cao; Jianchun Duan
• Keywords: QH301-705.5; early-stage; DNA damage response; molecular subtype; lung adenocarcinoma; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Molecular Biosciences; Biology (General); prognostic; signature

DNA damage response (DDR) pathways play a crucial role in lung cancer. In this retrospective analysis, we aimed to develop prognostic model and molecular subtype based on the expression profiles of DDR-related genes early-stage adenocarcinoma (LUAD). A total 1,785 samples from one RNA-seq dataset The Cancer Genome Atlas (TCGA) six microarray datasets Gene Expression Omnibus (GEO) were included analysis. TCGA dataset, gene (DRG)-based signature consisting 16 was constructed predict clinical outcomes LUAD patients. Patients low-DRG score group had better lower genomic instability. Then, same used DRG-based subtypes stratify into two (DRG1 DRG2) which significant differences outcomes. Kappa test showed good consistency between DRG (K = 0.61, p < 0.001). significantly associated with prognosis GEO (pooled estimates hazard ratio, OS: 0.48 (0.41-0.57), 0.01; DFS: 0.50 (0.41-0.62), 0.01). Furthermore, patients DRG2 benefited more adjuvant therapy than standard-of-care, not observed DRG1 group. summary, that potential guide selection for